Hormone Therapy News

Transgender women prescribed gender-affirming hormone therapy have a 47-fold higher risk for developing breast cancer during a median of 18 years vs. cisgender men, although this observed risk remained lower than that for cisgender women, according to findings published in The BMJ.

Infant boys born with a rare form of congenital hypogonadotropic hypogonadism, a condition associated with micropenis and undescended testes, experienced an improvement in symptoms after 3 months of combination treatment with two fertility hormones, according to findings published in the Journal of the Endocrine Society.

Endocrine Today has compiled a list of the top five news stories posted from the American Association of Clinical Endocrinologists Scientific & Clinical Congress, held April 24-28, 2019, in Los Angeles.

A cohort of young adults with Prader-Willi syndrome treated with growth hormone therapy as children did not meet criteria for adult GH deficiency after accounting for BMI; however, borderline-low GH levels continued to persist for some, according to findings published in Clinical Endocrinology.

Beginning today, an international athletic body will require that women with exceptionally high levels of testosterone use a hormonal contraceptive for at least 6 months if they wish to compete in races ranging from 400 meters to 1 mile, according to a spokesperson for the group.

NASHVILLE, Tenn. — Estrogen therapy in women ages 50 to 63 has been shown to affect the metabolic processes associated with later development of Alzheimer’s disease and may offer an opportunity to prevent or delay the disease, according to a presenter at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

NASHVILLE. Tenn. — Combined data from three phase 3 trials showed Agile Therapeutics’ investigational oral contraceptive patch AG200-15 had a safety profile similar to other approved contraceptives, according to data presented at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

NASHVILLE, Tenn. — The investigational drug bremelanotide enhanced sexual function in women regardless of the contraceptive used and its duration of use, according to data from two different abstracts presented at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

An international athletic body ruled Wednesday that women with several rare forms of hyperandrogenism must lower their natural testosterone levels for at least 6 months before competing in races ranging from 400 meters to 1 mile, according to a press release.

A small group of children with aggrecan deficiency, a rare genetic mutation that causes inherited short stature and early-onset joint disease, experienced a “robust” rate of growth after 6 months of recombinant human growth hormone treatment, according to study data presented at the Pediatric Endocrine Society annual meeting.